DK4028017T3 - 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme - Google Patents
1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme Download PDFInfo
- Publication number
- DK4028017T3 DK4028017T3 DK20788868.6T DK20788868T DK4028017T3 DK 4028017 T3 DK4028017 T3 DK 4028017T3 DK 20788868 T DK20788868 T DK 20788868T DK 4028017 T3 DK4028017 T3 DK 4028017T3
- Authority
- DK
- Denmark
- Prior art keywords
- nuak1
- lrrk2
- dihydrobenzo
- pyrazolo
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 title 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 title 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 title 1
- ORQJPWRNWPJVTJ-UHFFFAOYSA-N N1N=CC2=C1C1=C(N=CN2)C=CC=C1 Chemical class N1N=CC2=C1C1=C(N=CN2)C=CC=C1 ORQJPWRNWPJVTJ-UHFFFAOYSA-N 0.000 title 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 title 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899908P | 2019-09-13 | 2019-09-13 | |
| PCT/IB2020/000730 WO2021048620A1 (en) | 2019-09-13 | 2020-09-11 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4028017T3 true DK4028017T3 (da) | 2024-01-15 |
Family
ID=72801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20788868.6T DK4028017T3 (da) | 2019-09-13 | 2020-09-11 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220380374A1 (https=) |
| EP (2) | EP4327884A3 (https=) |
| JP (2) | JP7796007B2 (https=) |
| KR (1) | KR20220062038A (https=) |
| CN (2) | CN114793435B (https=) |
| AU (1) | AU2020344216A1 (https=) |
| CA (1) | CA3154123A1 (https=) |
| DK (1) | DK4028017T3 (https=) |
| ES (1) | ES2969088T3 (https=) |
| FI (1) | FI4028017T3 (https=) |
| HU (1) | HUE065093T2 (https=) |
| IL (1) | IL291335A (https=) |
| PL (1) | PL4028017T3 (https=) |
| PT (1) | PT4028017T (https=) |
| RS (1) | RS65045B1 (https=) |
| SI (1) | SI4028017T1 (https=) |
| WO (1) | WO2021048620A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7796007B2 (ja) * | 2019-09-13 | 2026-01-08 | オリゲニス ゲーエムベーハー | 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物 |
| JP2022548581A (ja) * | 2019-09-13 | 2022-11-21 | オリゲニス ゲーエムベーハー | 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物 |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2350086B1 (en) | 2008-09-23 | 2021-04-21 | The Johns Hopkins University | Fused diimidazodiazepine compounds and methods of use and manufacture thereof |
| AU2012244549B2 (en) * | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| JP7796007B2 (ja) * | 2019-09-13 | 2026-01-08 | オリゲニス ゲーエムベーハー | 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物 |
| JP2022548581A (ja) | 2019-09-13 | 2022-11-21 | オリゲニス ゲーエムベーハー | 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物 |
-
2020
- 2020-09-11 JP JP2022516097A patent/JP7796007B2/ja active Active
- 2020-09-11 PL PL20788868.6T patent/PL4028017T3/pl unknown
- 2020-09-11 FI FIEP20788868.6T patent/FI4028017T3/fi active
- 2020-09-11 EP EP23205855.2A patent/EP4327884A3/en active Pending
- 2020-09-11 WO PCT/IB2020/000730 patent/WO2021048620A1/en not_active Ceased
- 2020-09-11 US US17/642,142 patent/US20220380374A1/en not_active Abandoned
- 2020-09-11 CN CN202080078998.0A patent/CN114793435B/zh active Active
- 2020-09-11 RS RS20240045A patent/RS65045B1/sr unknown
- 2020-09-11 CN CN202411291626.2A patent/CN119775277A/zh active Pending
- 2020-09-11 HU HUE20788868A patent/HUE065093T2/hu unknown
- 2020-09-11 SI SI202030353T patent/SI4028017T1/sl unknown
- 2020-09-11 AU AU2020344216A patent/AU2020344216A1/en active Pending
- 2020-09-11 CA CA3154123A patent/CA3154123A1/en active Pending
- 2020-09-11 EP EP20788868.6A patent/EP4028017B1/en active Active
- 2020-09-11 DK DK20788868.6T patent/DK4028017T3/da active
- 2020-09-11 PT PT207888686T patent/PT4028017T/pt unknown
- 2020-09-11 ES ES20788868T patent/ES2969088T3/es active Active
- 2020-09-11 KR KR1020227011532A patent/KR20220062038A/ko active Pending
-
2022
- 2022-03-13 IL IL291335A patent/IL291335A/en unknown
-
2025
- 2025-02-26 JP JP2025028912A patent/JP2025081660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4028017T (pt) | 2024-01-16 |
| PL4028017T3 (pl) | 2024-03-18 |
| CA3154123A1 (en) | 2021-03-18 |
| IL291335A (en) | 2022-05-01 |
| SI4028017T1 (sl) | 2024-04-30 |
| FI4028017T3 (fi) | 2024-01-11 |
| EP4028017B1 (en) | 2023-12-06 |
| EP4327884A3 (en) | 2024-05-01 |
| HUE065093T2 (hu) | 2024-05-28 |
| WO2021048620A1 (en) | 2021-03-18 |
| CN114793435A (zh) | 2022-07-26 |
| RS65045B1 (sr) | 2024-02-29 |
| AU2020344216A1 (en) | 2022-03-31 |
| ES2969088T3 (es) | 2024-05-16 |
| JP2025081660A (ja) | 2025-05-27 |
| JP2022548246A (ja) | 2022-11-17 |
| EP4028017A1 (en) | 2022-07-20 |
| JP7796007B2 (ja) | 2026-01-08 |
| CN114793435B (zh) | 2024-10-01 |
| US20220380374A1 (en) | 2022-12-01 |
| CN119775277A (zh) | 2025-04-08 |
| KR20220062038A (ko) | 2022-05-13 |
| EP4327884A2 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| DK3658539T3 (da) | Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet | |
| DK3938047T3 (da) | Broforbundne tricykliske carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK3804714T3 (da) | Farmaceutisk kombination og sammensætning, og kombinationspræparat indeholdende glucokinase-aktivator og hypoglykæmisk biguanid-lægemiddel samt fremgangsmåde til fremstilling og anvendelse deraf | |
| DK3752510T3 (da) | Makrocyklusser som modulatorer af cystisk fibrose transmembrankonduktansregulator, farmaceutiske sammensætninger deraf, deres anvendelse i behandlingen af cystisk fibrose og fremgangsmåde til fremstilling deraf | |
| DK3801909T3 (da) | Kornmølle og valsestol med flere malepassager til optimeret maling af produkter samt tilsvarende fremgangsmåde | |
| SG11202107978RA (en) | Methods and system for the reconstruction of drug response and disease networks and uses thereof | |
| DK4028017T3 (da) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepinderivater og beslægtede forbindelser som lrrk2-, nuak1- og/eller tyk2- kinasemodulatorer til behandling af for eksempel autoimmune sygdomme | |
| DK3873884T3 (da) | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme | |
| CL2016002836A1 (es) | Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame). | |
| DK3658140T3 (da) | Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension | |
| DK3984523T3 (da) | Crf1-receptorantagonist, farmaceutiske formuleringer og faste former heraf til behandling af medfødt binyrebarkhyperplasi | |
| UY38338A (es) | INHIBIDORES DE LA INTERACCIÓN PROTEÍNA-PROTEÍNA KEAP1-Nrf2 | |
| HK1249500A1 (zh) | 作为ror调节剂的三环碸类 | |
| DK3894411T3 (da) | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-aminderivater og beslægtede forbindelser som gamma-sekretase-modulatorer til behandling af Alzheimers sygdom | |
| DK3509598T3 (da) | Ny anvendelse af triazolo(4,5-d)pyrimidinderivater til forebyggelse og behandling af bakteriel infektion | |
| DK3737684T3 (da) | 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-on-derivater og relaterede forbindelser som c5a-receptormodulatorer til behandling af vaskulitis og inflammatoriske sygdomme | |
| DK4003998T3 (da) | N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som au-totaxin (atx) modulatorer til behandlingen af inflammatorisk luftvejs- eller fibrotiske sygdomme | |
| DK3744316T3 (da) | Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3529234T3 (da) | Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser | |
| EP3730492A4 (en) | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| DK4031117T3 (da) | NGF-mutant til anvendelse i behandling eller forebyggelse af oftalmiske lidelser | |
| DK3763718T3 (da) | Substitueret 3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-6,8-dion, farmaceutisk sammensætning og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3823972T3 (da) | Imidazo[1,2-b]pyridazinderivater som trk-inhibitorer | |
| DK4036095T3 (da) | 4-fluor-1h-pyrazolo[3,4-c]pyridinderivater som selektive bruton-tyrosinkinase- (btk) inhibitorer til behandlingen af b-cellelymfom og autoimmunsygdomme |